Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

A rrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Plozasiran is not yet approved for commercial use in the U.S., but, as Healio previously reported, it received a breakthrough therapy designation from the FDA, and Arrowhead plans to file an ...

Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of Apolipoprotein C-III (APOC3) which is a component ...

Plozasiran is an investigational RNA interference therapeutic that targets the apolipoprotein C-III (ApoC-III) protein, which inhibits the liver's ability to clear triglycerides out of the body.

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final ...

- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated ...

Cardiology > Dyslipidemia Plozasiran Paves RNA Interference Path to Triglyceride Reduction — Clinical outcomes pending for people with elevated LDL cholesterol and triglycerides by Nicole Lou ...